Leerink Partners sets a price target of $40 for NASDAQ:IMNM, indicating a potential increase of approximately 76.6%.Immunome announces an underwritten public offering aiming to raise $400 million to advance cancer therapy developments.The stock price of IMNM has reached a yearly high of $25.30, with today's trading volume hitting 12.54 million shares.Immunome, Inc. (NASDAQ:IMNM) is a biotechnology company focused on developing innovative cancer therapies. On December 15, 2025, Leerink Partners set a price t ...

Takeda has struck a deal with China’s Innovent Biologics to co-develop cancer therapies https://t.co/agRWrXsEhB ...

Core Insights - Top executives and analysts emphasize the importance of consistent earnings growth as a reflection of a company's profitability, with earnings acceleration having a more significant impact on stock prices [1][3] - Successful stocks typically experience a speed-up in earnings before their stock prices rise, indicating potential investment opportunities [1][3] Earnings Acceleration - Earnings acceleration refers to the incremental growth in a company's earnings per share (EPS), specifically when the quarter-over-quarter earnings growth rate increases over time [2] - This metric helps identify stocks that have not yet attracted investor attention, which can lead to a subsequent rally in share prices [3] Screening Parameters - The screening process involves identifying stocks where the last two quarter-over-quarter EPS growth rates exceed previous periods' growth rates, with projected EPS growth rates for the upcoming quarter expected to surpass prior periods [5][6] - Additional criteria include a current price of at least $5 and an average 20-day trading volume of 50,000 or more to ensure adequate liquidity [7] Highlighted Stocks - QuantumScape Corporation (QS) is focused on developing solid-state lithium-metal batteries for electric vehicles, with an expected earnings growth rate of 17% for the current year [9] - Civeo Corporation (CVEO) provides hospitality services for the natural resource industry, projecting an earnings growth rate of 69.8% for the current year [10] - Agenus Inc. (AGEN) is a clinical-stage biotechnology company developing cancer therapies, with a leading projected earnings growth rate of 114.7% for the current year [11]